Lead author Nagy Mekhail, MD, PhD discusses the importance of neuromodulation, specifically a closed loop spinal cord stimulation system (SCS), for the management of chronic pain.
As a result of the vote, Nektar has decided to withdraw the New Drug Application for oxycodegol and to cease further development of the product.
Larger contralateral trigeminal nerve and hippocampus volumes are predictive of early nonresponse to surgical treatment of trigeminal neuralgia.
Spinal cord stimulation (SCS) with a closed-loop system that uses recorded evoked compound action potentials (ECAPs) is superior to a fixed-output, open-loop system for patients with chronic back and leg pain.
The Food and Drug Administration (FDA) has approved the Senza Omnia Spinal Cord Stimulation (SCS) System (Nevro) for the treatment of chronic intractable pain of the trunk and/or limbs.
Off-label antidepressant use for chronic pain has increased in recent years in part as a result of the opioid epidemic and the need to reduce prescribing and use of opioids for chronic pain.
Interventional pain modalities provide alternative analgesia in patients who are intolerant of pharmacologic agents, have comorbidities that require multiple medications, or have pain refractory to oral medications.
Sleep disturbance may be associated with reduced improvements in pain interference and pain severity in patients with chronic pain, regardless of whether they are treated with opioids.
There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.
Acupuncture may offer short-term benefits for leg pain associated with chronic discogenic sciatica.
